Working… Menu

Effectiveness and Safety of Salba on Weight Loss in Overweight Individuals With Type 2 Diabetes (LOSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01403571
Recruitment Status : Completed
First Posted : July 27, 2011
Last Update Posted : October 5, 2016
Canadian Diabetes Association
Information provided by (Responsible Party):
Unity Health Toronto

Brief Summary:

Canadian statistics indicate that the incidence of obesity is increasing and that the occurrence of diabetes in obese individuals is 5-fold greater than those with a healthy weight, making weight control in this population particularly relevant. Preliminary clinical data has shown that the whole grain, Salba, may improve type 2 diabetes control, reduce after-meal blood glucose, cardiovascular disease (CVD) risk factors and suppress appetite. Its use may therefore have potential implications in long-term weight management, while improving diabetes.

The objective of this research (weight loss) is to evaluate whether adding Salba to an energy reduced diet for six months will result in greater weight loss compared to control in overweight and obese individuals with type 2 diabetes. The study recruited 77 overweight or obese individuals with type 2 diabetes. They were instructed to follow a calorie restricted diet and their regular diabetes therapy together with regular exercise. Participants were randomly assigned to receive 30 g Salba/1000 kcal of daily energy requirements, or an oat bran control supplement matched for energy. The effect of the supplements on weight-loss (including waist circumference, % body fat) and glucose control (A1c, fasting glucose levels) will be assessed. In addition, related outcomes such as low-grade body inflammation, hunger-regulating hormones (ghrelin, adiponectin), safety measures (urea, creatinine, ALT and prothrombin time) and satiety scores were evaluated.

Modest weight loss has been associated with improved glucose control in individuals with type 2 diabetes. Addition of Salba to an energy reduced diet may facilitate greater weight loss and improve glycemic control and CVD risk factors compared to such a diet alone. Salba may also promote maintenance of weight loss and therefore help prevent weight gain by providing feelings of fullness that reduce appetite. In light of the high incidence of obesity in individuals with diabetes, Salba grain may be a useful addition to the diet.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Overweight Obesity Dietary Supplement: Salba (Salvia hispanica L.) Dietary Supplement: Oat-based Control Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 77 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Whole Grain Salba (Salvia Hispanica L.) on Weight Loss in Overweight and Obese Individuals With Type 2 Diabetes
Study Start Date : October 2009
Actual Primary Completion Date : August 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Salvia

Arm Intervention/treatment
Experimental: Salba supplement
Dietary Supplement: Salba (Salvia hispanica L.)
30g/1000kcal/day over 24 wks

Placebo Comparator: Oat-bran based Control Supplement
Dietary Supplement: Oat-based Control
Placebo: 36g/1000kcal/day over 24 weeks

Primary Outcome Measures :
  1. Weight [ Time Frame: 24 weeks ]
    24 week timeframe for Weightloss phase

Secondary Outcome Measures :
  1. Body composition [ Time Frame: 24 weeks ]
    24 week timeframe for Weightloss phase

  2. Blood sugar control [ Time Frame: 24 weeks ]
    (HbA1c and Fasting glucose) 24 week timeframe for Weightloss phase

  3. Low grade body inflammation [ Time Frame: 24 weeks ]
    hs-CRP levels

  4. serum ALT [ Time Frame: 24 weeks ]
    Safety Measures

  5. Prothrombin time [ Time Frame: 24 weeks ]
    Safety Measures

  6. serum creatinine [ Time Frame: 24 weeks ]
    Safety Measures

  7. Blood urea [ Time Frame: 24 weeks ]
    Safety Measures

  8. Satiety hormones [ Time Frame: 24 weeks ]
    ghrelin, adiponectin

  9. Fatty Acids (% composition) [ Time Frame: 24 weeks ]
    ALA (18:3 n-3), LA (18:2 n-6); Compliance measure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Well-controlled type 2 diabetes for at least 1 year
  • Treated with diet and/or oral hypoglycemic medications
  • BMI 25-40 kg/m2

Exclusion Criteria:

  • Weight change in the past three months >10% of body weight
  • On insulin therapy
  • Unstable angina, myocardial infarction or stroke (within 6 months)
  • Planned surgery or pregnancy
  • Blood pressure >160mmHg/100mmHg
  • Surgical procedures for weight loss and concomitant use of medication or supplements that alter body weight or appetite
  • ALA, dietary fibre, fish oil supplements or consuming cold-water fish more than three times per week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01403571

Layout table for location information
Canada, Ontario
Risk Factor Modification Centre, St. Michael's
Toronto, Ontario, Canada, M5B1W8
Sponsors and Collaborators
Unity Health Toronto
Canadian Diabetes Association
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Unity Health Toronto Identifier: NCT01403571    
Other Study ID Numbers: 2103038AJ
First Posted: July 27, 2011    Key Record Dates
Last Update Posted: October 5, 2016
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Weight Loss
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Body Weight
Body Weight Changes